Sales and Market Performance - Q1 2023 sales of OK lenses and care products improved significantly compared to Q4 2022, with a shift from decline to growth [2] - 47.4% of 2022 revenue came from terminal business, with over 300 terminals under company control [6] - OK lens market penetration is low due to concentration in large hospitals, limited service availability in smaller cities, and high consumer cost requirements [6] Product Development and Innovation - New product lines include reduced defocus glasses, red light eye care lamps, next-generation OK lenses, scleral lenses, and light therapy devices [4] - Next-generation OK lenses expected to complete clinical trials and submit registration in 2023 [4] - Scleral lenses address traditional RGP limitations and have significant application potential in China [4] Terminal Expansion Strategy - Company plans to expand terminal network through both new construction and acquisitions, prioritizing success rate over quantity [5] - Terminal expansion expected to significantly outperform 2022 results [3] - Regional terminal construction and management centers established to oversee investment and development [3] Industry Trends and Competitive Advantage - Non-medical system expected to remain mainstream for OK lens sales despite potential hospital channel growth through centralized procurement [3] - Future eye care terminal channels predicted to follow developed country models with both hospital-based and community-based clinics [3] - Company maintains comprehensive competitive advantages in R&D, brand, sales network, partnerships, and talent development [4] Financial and Investment Activities - Company participated in establishing new investment funds (Yingfeinidi and Shanlan) to expand investment scale and improve quality [6] - Industrial fund investments have shown success, with participation in USTC Silicon Valley platform company [6] Production Capacity - Two new OK lens production lines in debugging phase, expected to start production next month [6] - Two additional production lines planned for year-end completion [6] - Production capacity expansion typically occurs during off-peak seasons (summer and winter breaks) [6]

欧普康视科技股份有限公司 2022 年年度报告全文 股票简称：欧普康视 证券代码：300595 编号：2023-020 欧普康视科技股份有限公司 股票代码：300595 2023 年 04 月 中国 ▪ 合肥 1 欧普康视科技股份有限公司 2022 年年度报告全文 2022 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个 别和连带的法律责任。 公司负责人陶悦群、主管会计工作负责人卫立治及会计机构负责人(会计 主管人员)王畅、王静、陈艳、丁伯明声明：保证本年度报告中财务报告的真 实、准确、完整。 2022 年年度报告 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司 对任何投资者及相关人士的实质承诺，投资者及相关人士均应对此保持足够 的风险认识，并且应当理解计划、预测与承诺之间的差异。 一、国家行业政策的变化和产品法律风险 1、行业政策变化的风险 公司从事的业务属于"医用光学器具、仪器及内窥镜设备"中的"植入 体内或长期接触体内的 ...